Adacel Approved for Repeat Vaccination Against Tetanus, Diphtheria, Pertussis
The approval was based on data from the Td537 study which included individuals 18-64 years old who had received a dose of Adacel 8-12 years prior (N=1330).
All articles by Tony Morbin
Global Demand for Bladder Cancer Treatment Threatens Supply in 2019
TICE BCG is indicated for the treatment and prophylaxis of carcinoma in situ of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection.
Supply Updates Announced for Recombivax HB Vaccines
The information, posted to the Food and Drug Administration (FDA) website, states that both the Recombivax HB adult (10mcg/mL) and dialysis (40mcg/mL) formulations are not expected to be available in 2019.
Statin Use After HCC Diagnosis Linked to Reduced Risk of Death
Among the HCC patients included in the analysis, 14.9% (N=2293) were recorded as having used a statin after diagnosis.
Finasteride Uses, Efficacy Examined in Female Patients
Off-label use has become more common in women for treatment of alopecia and hirsutism.
Primatene MIST Now Available OTC for Mild Symptoms of Intermittent Asthma
The Primatene MIST inhaler contains 160 metered sprays and is available nationwide at Walgreens stores and online at Walgreens and CVS.
Health Experts Review 41 Diets, Rank Best Overall for 2019
An expert panel assessed 41 diets to come up with their final results, examining the evidence behind each diet’s claims, the short-term and long-term weight loss associated with the diet, how easy the diet is to follow, how well each diet conforms to current nutrition standards, and its effect on diabetes and cardiovascular disease prevention.
RNA-Based Oligonucleotide Gets Fast-Tracked for Usher Syndrome Type 2
The treatment will be investigated in a Phase 1/2 safety and tolerability trial (STELLAR) where patients (N=18) will receive either a single dose administration of QR-421a via intravitreal injection or a sham procedure.
Ravicti Approved for Children Under 2 Months With Urea Cycle Disorders
The approval was based on a study that assessed the safety, efficacy, and pharmacokinetics of Ravicti in 16 patients with UCDs less than 2 months of age.
Treatment for Acute Agitation Gets Fast Track Designation
According to the Company, a Phase 1 placebo-controlled, dose-escalation study of BXCL501 is expected to enroll up to 60 healthy adults across various dosing groups; pharmacokinetics and safety will be evaluated as primary endpoints.
